Bank of America’s $250 Million GLP-1 Bill

Bank of America spends $250 million annually on GLP-1 medications for its employees, Chief Executive Brian Moynihan said this week, placing a concrete dollar figure on the surging cost of a drug class that has redefined weight-loss treatment and is increasingly consuming corporate health budgets.

The figure, reported by CNBC, covers drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound—medicines that initially targeted diabetes but are now widely prescribed for weight management. Bank of America, the second-largest U.S. bank by assets, employs over 200,000 people, meaning the GLP-1 spend translates to roughly $1,180 per employee each year. That is a significant line item even for a company whose total healthcare spending likely runs into the billions.

The disclosure comes as large employers across the U.S. confront an unprecedented surge in pharmacy costs. Surveys by the Business Group on Health have consistently identified GLP-1 drugs as the number one driver of prescription drug spending increases. While many companies still cover the drugs to remain competitive in talent markets, the accelerating price tag is forcing a re-evaluation of how widely and under what conditions they are accessible.

What the BofA Disclosure Signals for Employer Health Costs

Why the $250 Million Figure Matters

By itself, $250 million is a striking number, but its real significance lies in what it signals about the new normal for employer-sponsored health plans. Bank of America is not an outlier. Employers of similar size—Walmart, Amazon, JPMorgan Chase—are all wrestling with ballooning costs tied to GLP-1 medications. BofA’s disclosure provides a concrete benchmark against which other companies can measure their own exposure, revealing that a large, self-insured employer can spend well over $1,000 per employee each year on a single drug class.

Advertisement

Pressure on Company Health Plans

Most large employers self-fund their health benefits, meaning they bear the direct financial risk of rising drug costs. As GLP-1s gain approval for new indications—cardiovascular risk reduction, chronic kidney disease, and potentially Alzheimer’s—the eligible patient population could expand dramatically. Even without new approvals, the current demand is so strong that employers are already tightening access through prior authorization rules, step therapy requirements, and, in some cases, outright exclusions from formularies. The BofA disclosure may accelerate these types of utilization management across corporate America as CFOs and benefits managers look to rein in costs without angering employees.

Pharma’s Heavy Reliance on Employer Coverage

For drugmakers Novo Nordisk and Eli Lilly, employer-sponsored commercial plans are a critical revenue channel. High list prices—often exceeding $1,000 per month before rebates—are sustained in large part because large employers with self-insured plans have historically absorbed the cost. As that willingness wanes, manufacturers could face greater pressure to negotiate larger discounts or to restructure pricing through value-based agreements. The BofA number, if it inspires other employers to disclose their own spending, could shift the negotiating dynamic between pharmacy benefit managers (PBMs), insurers, and pharmaceutical companies.

What It Means for Insurers and PBMs

Health insurers and PBMs are caught in the middle. They must balance the clinical demand for effective obesity treatments with the financial sustainability of the plans they administer. Some have already begun experimenting with limited-duration coverage programs and lifestyle coaching mandates. The BofA snapshot will likely embolden these efforts and may lead to the development of new reinsurance or stop-loss products specifically designed to cap employer liability for high-cost drug classes.

How Other Employers Can Respond to the GLP-1 Spending Surge

  • Benchmark your own GLP-1 spend: Calculate per-employee costs and compare against Bank of America’s estimated $1,180 per employee. Use the gap to set realistic budget targets for the next plan year.
  • Revisit formulary placement and access rules: Review prior authorization criteria, step therapy protocols, and quantity limits to ensure that coverage is targeted at evidence-based use without creating unnecessary barriers for employees with a clinical need.
  • Negotiate value-based contracts: Use the BofA disclosure as leverage in discussions with manufacturers and PBMs to link pricing to health outcomes or to cap per-member-per-year costs for GLP-1s.
  • Model the impact of expanding indications: Scenario-plan for FDA approvals of GLP-1s for additional conditions such as cardiovascular disease or kidney disease, which could double or triple the eligible population within your plan.
  • Bundle clinical support programs: Pair coverage with integrated wellness or health coaching programs that help ensure the drugs are used as part of a comprehensive treatment plan, potentially reducing wasteful utilization and improving long-term health outcomes.

Risk & Opportunity Assessment

Commercial RiskHighUnchecked growth in GLP-1 spending could materially inflate employer healthcare costs. Bank of America’s $250 million annual spend implies that large, self-insured employers may see this drug class consume a significant and rising share of their benefits budget, straining operating margins.
Competitive RiskMediumCompanies that adopt more effective cost-management strategies could reduce their per-employee healthcare expense advantageously. However, because most large employers face the same cost pressures, the risk of a single company gaining a decisive advantage is limited.
Regulatory RiskMediumFederal and state policymakers are increasingly scrutinizing drug pricing and pharmacy benefit manager practices. Government action—such as price caps or mandatory transparency requirements—could alter the cost structure for GLP-1s, with variable effects on employer plans.
Reputation RiskLowRestricting access to popular weight-loss medications could lead to employee dissatisfaction or negative media coverage if perceived as denying needed care. For now, most large employers continue to cover the drugs, limiting immediate reputational fallout.
Technology DisruptionLowThe cost challenge is driven by pharmaceutical pricing and demand, not by technological displacement. Digital therapeutics or other non-pharmacological weight-loss tools could complement GLP-1 use but are unlikely to replace the drug class in the near term.
Commercial OpportunityHighInsurers, PBMs, and health-tech firms that develop cost-containment solutions—such as predictive analytics for utilization, value-based pricing models, or integrated patient support programs—could capture new revenue from employers desperate to manage GLP-1 expenses.